Navigation Links
Record Year for CEM's Peptide Synthesis Business
Date:7/27/2011

MATTHEWS, N.C., July 27, 2011 /PRNewswire/ -- CEM Corporation, a leading global provider of microwave laboratory instrumentation, continues to see strong success with its microwave peptide synthesis products. In FY2011 year-to-date, the company has seen significant growth versus the prior year in its automated peptide synthesizer instrument sales and is on pace to easily sell a record number of systems. Additionally, CEM's products were well received at the recent American Peptide Symposium, which was held June 25-30, 2011 in San Diego, CA, including its new semi-automated microwave peptide synthesizer, the Discover® SPS Plus.

(Logo: http://photos.prnewswire.com/prnh/20090622/CL35336LOGO-b)

"We are very pleased with our successful results this year," said Michael J. Collins, president and CEO of CEM Corporation. "They continue to demonstrate that CEM is the leader in peptide synthesis. Our technology is now broadly accepted and has been transformational in enhancing peptide synthesis."

CEM has been awarded multiple patents related to the use of microwave energy for peptide synthesis(1). CEM's patented process uses microwave energy to enhance both the deprotection and coupling steps in manual and automated peptide synthesis. This means that other microwave peptide synthesizers (manual or automated) are limited to applying microwave energy only in the deprotection or coupling step in a single vessel.

"An average length peptide contains many deprotection and coupling steps. As incomplete reactions are routinely observed in both steps, it is a significant disadvantage to use microwave energy for only one of the two reactions at each cycle," explained Collins. "Our patented process is faster and results in higher purity peptides, giving CEM a long-term advantage in the field."

Access to the patented process is included with the purchase of any of CEM's manual, semi-automated, or fully automated peptide synthesizers. This technology is not available with other microwave peptide synthesizers.

CEM designed, developed, and introduced the world's first microwave peptide synthesizer to the scientific community in 2003. Since that time, CEM has expanded its portfolio to include manual, semi-automated, fully automated (single channel), and fully automated (12-channel) systems. All of CEM's peptide synthesizers can operate under conventional conditions, microwave conditions, or a combination of both. Both fully automated systems can be equipped with an optional UV monitoring system. Additionally, the manual and semi-automated systems can be upgraded to either of the fully automated versions.

Each one of CEM's peptide synthesizers utilizes in-situ fiber optic temperature monitoring during heating. In-situ temperature monitoring helps avoid temperature overshoots from use of external IR monitoring, which can lead to significant side reactions. In 2007, researchers at CEM showed in a major publication that precise temperature control limits major side reactions such as racemization and aspartimide formation(2).   CEM's methods are now routinely used in hundreds of laboratories worldwide.

(1) Including among others US7,563,865; US7,582,728; US7,393,920, EP1491552. Additional International Patents filed and pending.

(2) Palasek S., Cox Z., Collins J., J. Pept. Sci.13,143-148, 2007.

CEM Corporation, a private company based in Matthews, North Carolina, is the leading global company specializing in scientific solutions for critical laboratory applications. The Company has subsidiaries in the United Kingdom, Germany, Italy, France, and Japan, as well as a global network of distributors. CEM designs and manufactures systems for bioscience applications, life sciences, analytical laboratories and processing plants worldwide. The Company's products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research.


'/>"/>
SOURCE CEM Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
2. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
3. China Kangtai Cactus Biotech Announces Record Second Quarter Results
4. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
5. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
6. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
7. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Octapharma USA Retains Yankee Public Relations as its Agency of Record
10. Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
11. Womens Surgery Recorded for the First Time on 4K Digital Cinema is Presented at the AAGL Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... ... and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking forward to ... (PDA), the New York Interphex Show will open on March 21 and run through ... the educational and networking opportunities are extremely valuable. INTERPHEX is viewed as the key ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen Therapeutics Inc., an ... it has entered into an exclusive global license agreement with Children’s Hospital Los ... Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. ...
(Date:3/20/2017)... ... 2017 , ... The fourth annual Hackaday Prize , which aims to ... on peoples’ lives, launches today. Sponsored by Digi-Key and Microchip , ... in cash prizes to engineers, inventors and tinkerers who “build something that matters.” , ...
(Date:3/20/2017)... -- Western Institutional Review Board ® (WIRB™), the ... announced today the launch of its WIRB NIH ... multi-site research. As the long-standing leader in supporting IRB ... extensive background in reviewing clinical trials funded by NIH.  ... record for the majority of institutions that conduct clinical ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
Breaking Biology News(10 mins):